<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025072</url>
  </required_header>
  <id_info>
    <org_study_id>SIK-FR-21-1</org_study_id>
    <nct_id>NCT05025072</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers</brief_title>
  <official_title>A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Siklos® in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ADDMEDICA SASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simbec Orion</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oncodesign SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PHINC DEVELOPMENT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ADDMEDICA SASA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase I, open-label, single-centre, randomised, two-period, single-dose&#xD;
      crossover study to compare and assess the bioequivalence, safety, tolerability and&#xD;
      pharmacokinetics of hydroxycarbamide dispersible tablets (20 x 50 mg) (test IMP) and Siklos®&#xD;
      film-coated tablet (1000 mg) (reference IMP) following single-dose administration. Thirty&#xD;
      (30) healthy male and female participants, between 18 and 50 years of age are planned to&#xD;
      participate in the study.&#xD;
&#xD;
      Study participants will be randomised to one of the 2 possible combination sequences. After&#xD;
      each treatment administration, blood samples will be collected at specific time points to&#xD;
      assess the Pharmacokinetics (PK) parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2021</start_date>
  <completion_date type="Actual">September 29, 2021</completion_date>
  <primary_completion_date type="Actual">September 29, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 hours</time_frame>
    <description>The observed maximum concentration (Cmax) in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>24 hours</time_frame>
    <description>The area under the plasma concentration-time curve from time zero (pre-dose) to the time of last quantifiable concentration (t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-infinity</measure>
    <time_frame>24 hours</time_frame>
    <description>The AUC from time 0 to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>24 hours</time_frame>
    <description>The time at which Cmax is apparent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>24 hours</time_frame>
    <description>The terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ke</measure>
    <time_frame>24 hours</time_frame>
    <description>The terminal elimination rate-constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC%extra</measure>
    <time_frame>24 hours</time_frame>
    <description>% of AUC0-infinity extrapolated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence of Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Test IMP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydroxycarbamide dispersible tablets (20 x 50 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference IMP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxycarbamide film-coated tablet (1000 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxycarbamide dispersible tablets</intervention_name>
    <description>Hydroxycarbamide dispersible tablets (20 x 50 mg)</description>
    <arm_group_label>Reference IMP</arm_group_label>
    <arm_group_label>Test IMP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxycarbamide film-coated tablet</intervention_name>
    <description>Hydroxycarbamide film-coated tablet (1000 mg)</description>
    <arm_group_label>Reference IMP</arm_group_label>
    <arm_group_label>Test IMP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and female participants, between 18 and 50 years of age, inclusive.&#xD;
&#xD;
          2. Female participant of childbearing potential willing to use a highly effective method&#xD;
             of contraception, if applicable from the first dose until 3 months after the last dose&#xD;
             of IMP.&#xD;
&#xD;
          3. Female participant of non-childbearing potential. For the purposes of this study, this&#xD;
             is defined as the participant being amenorrhoeic for at least 12 consecutive months or&#xD;
             at least 4 months post-surgical sterilisation.&#xD;
&#xD;
          4. Female participant with a negative pregnancy test at Screening.&#xD;
&#xD;
          5. Male participant (and partner of child bearing potential) willing to use a highly&#xD;
             method of contraception, if applicable from first dose until 3 months after last dose&#xD;
             of IMP.&#xD;
&#xD;
          6. Participant with a BMI of 18-29.9 kg/m2.&#xD;
&#xD;
          7. No clinically significant history of previous allergy / sensitivity to&#xD;
             hydroxycarbamide or any of the excipients contained within the IMP(s).&#xD;
&#xD;
          8. No clinically significant abnormal test results for serum biochemistry, haematology&#xD;
             and/or urine analyses within 28 days before the first dose administration of the IMP.&#xD;
&#xD;
          9. Participant with a negative urinary DOA screen (including alcohol) test results,&#xD;
             determined within 28 days before the first dose administration of the IMP.&#xD;
&#xD;
         10. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HBsAg) and hepatitis C virus antibody (HCV Ab) test results at Screening.&#xD;
&#xD;
         11. No clinically significant abnormalities in 12-lead ECG determined within 28 days&#xD;
             before the first dose of IMP.&#xD;
&#xD;
         12. No clinically significant abnormalities in vital signs determined within 28 days&#xD;
             before the first dose of IMP.&#xD;
&#xD;
         13. Participant must be available to complete the study.&#xD;
&#xD;
         14. Participant must satisfy an Investigator about his/her fitness to participate in the&#xD;
             study.&#xD;
&#xD;
         15. Participant must provide written informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A clinically significant history of gastrointestinal disorder likely to influence IMP&#xD;
             absorption.&#xD;
&#xD;
          2. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements within 28 days or 5 half-lives prior to the first dose of IMP.&#xD;
&#xD;
          3. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or&#xD;
             metabolic dysfunction.&#xD;
&#xD;
          4. A clinically significant history of drug or alcohol abuse within the past two years.&#xD;
&#xD;
          5. Inability to communicate well with the Investigators.&#xD;
&#xD;
          6. Participation in a New Chemical Entity clinical study within the previous 3 months or&#xD;
             five half-lives whichever is the longest, or a marketed drug clinical study within the&#xD;
             30 days or five half-lives whichever is the longest, before the first dose of IMP.&#xD;
&#xD;
          7. Donation of 450 mL or more blood within the 3 months before the first dose of IMP.&#xD;
&#xD;
          8. Users of nicotine products i.e., current smokers or ex-smokers who have smoked within&#xD;
             6 months prior to Screening or users of cigarette replacements&#xD;
&#xD;
          9. Female participants who are pregnant, breastfeeding or lactating.&#xD;
&#xD;
         10. Participants who have received any live or attenuated vaccine within 28 days of the&#xD;
             first dose of IMP, or who are planning to receive a vaccine up to 28 days after&#xD;
             receiving the last dose of IMP in Treatment Period 2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annelize Koch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Orion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec-Orion Clinical Pharmacology</name>
      <address>
        <city>Merthyr Tydfil</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hydroxycarbamide</keyword>
  <keyword>Hydroxyurea</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

